Amundi Decreases Stake in Inspire Medical Systems, Inc. (NYSE:INSP)

Amundi lessened its stake in Inspire Medical Systems, Inc. (NYSE:INSP) by 10.0% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 203,353 shares of the company’s stock after selling 22,479 shares during the quarter. Amundi’s holdings in Inspire Medical Systems were worth $37,698,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. First Horizon Advisors Inc. increased its holdings in Inspire Medical Systems by 885.7% in the fourth quarter. First Horizon Advisors Inc. now owns 138 shares of the company’s stock valued at $26,000 after buying an additional 124 shares in the last quarter. True Wealth Design LLC acquired a new stake in shares of Inspire Medical Systems in the 3rd quarter worth approximately $30,000. Farther Finance Advisors LLC increased its stake in Inspire Medical Systems by 1,158.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 151 shares of the company’s stock valued at $32,000 after purchasing an additional 139 shares in the last quarter. Smartleaf Asset Management LLC raised its holdings in Inspire Medical Systems by 178.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 357 shares of the company’s stock worth $66,000 after purchasing an additional 229 shares during the last quarter. Finally, Nisa Investment Advisors LLC boosted its position in Inspire Medical Systems by 37.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 368 shares of the company’s stock worth $68,000 after purchasing an additional 100 shares in the last quarter. Institutional investors and hedge funds own 94.91% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on INSP. Bank of America upgraded Inspire Medical Systems from a “neutral” rating to a “buy” rating and raised their price target for the company from $220.00 to $255.00 in a research report on Wednesday, November 20th. Robert W. Baird dropped their target price on shares of Inspire Medical Systems from $252.00 to $248.00 and set an “outperform” rating for the company in a report on Tuesday, February 11th. Wells Fargo & Company reduced their price target on shares of Inspire Medical Systems from $198.00 to $195.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 11th. Truist Financial dropped their price objective on shares of Inspire Medical Systems from $250.00 to $235.00 and set a “buy” rating for the company in a research note on Tuesday, February 11th. Finally, Stifel Nicolaus reduced their target price on Inspire Medical Systems from $200.00 to $190.00 and set a “hold” rating on the stock in a research note on Tuesday, January 21st. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, Inspire Medical Systems has a consensus rating of “Moderate Buy” and an average target price of $228.82.

Inspire Medical Systems Stock Performance

Shares of INSP opened at $163.01 on Thursday. Inspire Medical Systems, Inc. has a fifty-two week low of $123.00 and a fifty-two week high of $257.40. The stock has a fifty day moving average of $186.26 and a two-hundred day moving average of $192.40. The company has a market capitalization of $4.84 billion, a PE ratio of 94.22, a price-to-earnings-growth ratio of 2.86 and a beta of 1.48.

Inspire Medical Systems (NYSE:INSP) last released its earnings results on Monday, February 10th. The company reported $1.15 EPS for the quarter, beating the consensus estimate of $0.74 by $0.41. Inspire Medical Systems had a return on equity of 8.19% and a net margin of 6.67%. As a group, equities research analysts forecast that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current fiscal year.

Insider Transactions at Inspire Medical Systems

In other news, insider Randy Ban sold 25,584 shares of the firm’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $183.50, for a total value of $4,694,664.00. Following the transaction, the insider now directly owns 7,259 shares in the company, valued at $1,332,026.50. This trade represents a 77.90 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CTO John Rondoni sold 583 shares of the business’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $170.49, for a total value of $99,395.67. Following the sale, the chief technology officer now owns 10,424 shares of the company’s stock, valued at $1,777,187.76. The trade was a 5.30 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 26,225 shares of company stock worth $4,806,530 in the last three months. Company insiders own 4.10% of the company’s stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.